期刊名称：PHARMACEUTICAL STATISTICS ISSN： 1539-1604 出版频率： Bi-monthly 出版社： WILEY, 111 RIVER ST, HOBOKEN, USA, NJ, 07030-5774   出版社网址： http://onlinelibrary.wiley.com/ 期刊网址： http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1539-1612 影响因子： 1.894 主题范畴： PHARMACOLOGY & PHARMACY;    STATISTICS & PROBABILITY 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Pharmaceutical Statistics is an industry-led initiative, tackling real problems in statistical applications. The Journal will publish papers which share experiences in the practical application of statistics within the pharmaceutical industry. It will cover all aspects of statistical applications in the industry from discovery, through pre-clinical development, clinical development, post-marketing surveillance, consumer health, production, epidemiology, and health economics. The Journal will be both international and multidisciplinary reflecting the nature of the pharmaceutical industry. It will include high quality practical papers, case studies and review papers. Each issue will feature a Teacher’s Corner, Consultant’s Forum, Reviews and Viewpoint sections. Purely theoretical papers will not be accepted. The aims of the Journal are to: Disseminate information and practical examples of the use of statistics in all stages of drug development, from discovery to production. Debate the ways in which the practice and application of statistics within the industry can best be developed; and to discuss and bring awareness to regulatory guidance documents. Draw upon and promote the full range of statistical methods and statistical thinking within the pharmaceutical industry. Provide a vehicle for communication between practitioners, researchers, educators and policy makers concerned with the application of statistics within drug development. Provide guidance and tutorials to statisticians working within the pharmaceutical industry. It is intended that both the readers and authors of the Journal include statisticians working in the pharmaceutical industry and, because of its non-theoretical nature, also non-statisticians such as clinicians, toxicologists, biologists, biochemists, chemists and genomic scientists. Instructions to Authors INITIAL MANUSCRIPT SUBMISSION. To facilitate swift peer review, Pharmaceutical Statistics operates a web-based submission, peer review and manuscript tracking system. Authors are required to submit their articles online. Please visit the following URL to create your personal account and to submit a manuscript. http://pst-wiley.manuscriptcentral.com/ Authors must also supply by mail at the time of initial submission: a Copyright Transfer Agreement with original signature(s) - without this we are unable to accept the submission, and permission grants - if the manuscript contains extracts, including illustrations, from other copyright works (including material from online or intranet sources) it is the author's responsibility to obtain written permission from the owners of the publishing rights to reproduce such extracts using the Wiley Permission Request Form. Permission grants should be submitted with the manuscript. Submitted manuscripts should not have been previously published and should not be submitted for publication elsewhere while they are under consideration by Wiley. FINAL SUBMISSION. The electronic copy of the final, revised manuscript must be uploaded to the online submission site in accordance with the instructions emailed to the author. We are able to use most word processing packages, but prefer Word or WordPerfect and TeX or one of its derivatives. If supplying TeX please supply a PostScript format plus the original source files. Manuscript style. The language of the journal is English. All submissions including book reviews must have a title, be double-line spaced and have a margin of 3cm all round. The title page must list the full title, short title, and names and affiliations of all authors. Give the full address, including email, telephone and fax, of the author who is to check the proofs. Include the name(s) of any sponsor(s) of the research contained in the paper, along with grant number(s). Supply a summary for all articles except book reviews. This should be a concise summary of the whole paper, not just the conclusions, and should be understandable without reference to the rest of the paper. It should contain no citation to other published work. Include up to six key words that describe your paper for indexing purposes. Letters to the Editors are welcomed and will be published at their discretion. Authors will be given the opportunity to respond to letters which comment upon their papers. Reference style. References should be cited by superior numbers and listed at the end of the paper in the order in which they appear in the text. All references must be complete and accurate. Where possible the DOI for the reference should be included at the end of the reference. Online citations should include date of access. If necessary, cite unpublished or personal work in the text but do not include it in the reference list. References should be listed in the following style: (Journals) Steiner SH, Cook RJ, Farewell VT. Monitoring paired binary surgical outcomes using cumulative sum charts. Pharmaceutical Statistics 2001; 18:69-86. DOI: 10.1002/pst.102 (Books) Senn S. Crossover trials in clinical research. Wiley: Chichester, 1993; pp 1-22. Illustrations. Supply each illustration separately (NOT integrated into the text), preferably in TIFF or EPS format, and include the source file. We favour dedicated illustration packages over tools such as Excel or Powerpoint. Ensure the lead author's name; the figure number; and the correct orientation are indicated. Tints are not acceptable; lettering must be of a reasonable size that would still be clearly legible upon reduction, and consistent within each figure and set of figures. Supply artwork at the intended size for printing. Copyright. To enable the publisher to disseminate the author's work to the fullest extent, the author must sign a Copyright Transfer Agreement, transferring copyright in the article from the author to the publisher, and submit the original signed agreement at the time of initial submission. A copy of the agreement to be used (which may be photocopied) will be reproduced in each volume of Pharmaceutical Statistics. Copies may also be obtained from the journal editor or publisher, or may be printed from this website. Copyright forms should be sent to: PSI Executive Office, Resources for Business, South Park Road, Macclesfield, Cheshire, SK11 6SH, UK Further Information. Proofs will be sent to the author for checking. This stage is to be used only to correct errors that may have been introduced during the production process. Prompt return of the corrected proofs, preferably within two days of receipt, will minimise the risk of the paper being held over to a later issue. Twenty-five complimentary offprints will be provided to the author who checked the proofs, unless otherwise indicated. Further offprints and copies of the journal may be ordered. There is no page charge to authors. Editorial Board EDITORS-IN-CHIEF Larry Furlong Director Statistical Science AstraZeneca Alderley Park Macclesfield Cheshire SK10 4TG U.K. E-mail: larry.furlong@astrazeneca.com  Steven A. Julious Senior Lecturer in Medical Statistics Medical Statistics Group Health Services Research University of Sheffield Regent Court 30 Regent Street Sheffield S1 4DA U.K. E-mail: S.A.Julious@Sheffield.ac.uk  Sue-Jane Wang Associate Director, Office of Biostatistics OPaSS, CDER, FDA 10903 New Hampshire Ave. Silver Spring, MD 20993 U.S.A. E-mail: sjwang@verizon.net  SECTION EDITORS Teachers Corner Richard Kay Independent Statistical Consultant,U.K Consultants Forum Scott Patterson GlaxoSmithKline, U.S.A Viewpoint Stephen Senn University College London, U.K. Christy Chuang-Stein Pfizer Inc, U.S.A  Literature Reviews Simon Day Medicines and Healthcare Products Regulatory Agency, U.K. Scott Patterson GlaxoSmithKline, U.S.A  Book Reviews Peter Lane GlaxoSmithKline, U.K.  Software Reviews John Salkeld Pfizer, U.K.  EDITORIAL ADVISORY BOARD Reinhard Bergmann Novartis Pharma Research Ltd. Switzerland Dennis Chanter StatisfAction Statistical Consultancy Ltd U.K. Darryl Downing GlaxoSmithKline U.S.A. Alan Ebbutt GlaxoSmithKline U.K. Stuart Ellis Zeneca Pharmaceuticals U.K. Val Fedorov GlaxoSmithKline U.S.A. Andy Grieve Pfizer Central Research U.K. Philip Hougaard Lundbeck Denmark Merete Joergensen Novo Nordisk A/S Denmark Meinhard Kieser Schwabe Pharmaceuticals Germany Gary Koch The University of North Carolina U.S.A. John Lewis Statistical and Regulatory Consultant to the Pharmaceutical Industry U.K. Dennis Lendrem TTC Consultants Ltd, U.K.   Karl Lin U.S. Food and Drug Administration U.S.A. Walter Offen Lilly Coporate Center U.S.A. Yasuo Ohashi University of Tokyo Japan John Parrott Pfizer U.K. Max Porter GlaxoSmithKline U.K. Amy Racine-Poon Novartis Pharma Inc. Switzerland Frank Rockhold GlaxoSmithKline U.S.A. Barry Schwab Johnson & Johnson U.S.A. Jorgen Seldrup Quintiles France Fred Snikeris Sanofi Pharmaceuticals, Inc U.S.A.   Thomas Vidmar Pfizer U.S.A. Henry Wynn University of Warwick U.K.